To explore a novel method to use @entity2642 in heavily treated @entity1 , 4-week cycles of high-dosage (280 mg/d) @entity14027 were given to 11 asymptomatic @entity1 who had previously received an average of 6 years of @entity2353 reverse transcriptase inhibitors (NRTIs). The @entity14027 dose was targeted to produce a calculated steady-state concentration of 1.5 microM (336 ng/mL). @entity1 received @entity14027 for the first 4 weeks, after which it was discontinued for 4 weeks. Additional 4-week drug cycles were given if plasma @entity2858 RNA levels increased to at least 75% of baseline values. The 11 subjects received 38 cycles (average, 3.5 cycles per subject) during the 44-week study. @entity14027 was well tolerated. Considering all data, there was a median 0.65 log(10) reduction in viral load as well as a median increase in CD4 cell count of 110/mm3 at the end of the cycles. However, plasma @entity646 increased and CD4 cell counts decreased between cycles. Viral load and CD4 cell responses were similar for up to 4 successive cycles. This suggested that increasing viral resistance was not a problem, as reflected by the acquisition of only one new @entity2353 reverse transcriptase mutation among the @entity1 . Significant relationships between @entity14027 exposure and changes in plasma @entity645 RNA levels were observed. A similar approach might be considered using a more potent regimen for @entity1 in whom resistance to @entity2642 is a major reason for therapeutic failure.

Intermittent administration of high-dose XXXX to @entity2353 -experienced individuals infected with @entity2858 .

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'Participants'] @entity2642 :: ('MESH:D009705', 'Chemical') :: ['nucleosides'] @entity2353 :: ('CHEBI:33838', 'Chemical') :: ['nucleoside'] @entity646 :: ('MESH:D014766', 'Disease') :: ['viremia'] @entity14027 :: ('MESH:D018119', 'Chemical') :: ['Stavudine', 'stavudine'] @entity2858 :: ('11676', 'Species') :: ['HIV-1'] @entity645 :: ('57667', 'Species') :: ['HIV']
@entity14027 :: (MESH:D018119,Chemical) :: ['stavudine']
